Multisite Performance Evaluation of an Enzyme-Linked Immunosorbent Assay for Detection of *Giardia*, *Cryptosporidium*, and *Entamoeba histolytica* Antigens in Human Stool

Nathaniel C. V. Christy,* Janice D. Hencke,b Alealya Escueta-De Cadiz,c Forida Nazib,c Deirud von Thien,a Kenji Yagita,c Segni Ligaba,a Rashidul Haque,d Tomoyoshi Nozaki,c Egbert Tannich,e Joel F. Herbein,b and William A. Petri, Jr.a

Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA;a; TechLab Inc., Blacksburg, Virginia, USA;b; Department of Parasitology, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan;c; International Center for Diarrheal Disease Research, Bangladesh; Dhaka, Bangladesh;d; Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany;e; and Graduate School of Life and Environmental Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan

A novel fecal antigen detection assay for fresh and frozen human samples that detects but does not differentiate *Giardia* spp, *Cryptosporidium* spp, and *Entamoeba histolytica*, the Tri-Combo parasite screen, was compared to three established enzyme-linked immunosorbent assays (ELISAs) at three international sites. It exhibited 97.9% sensitivity and 97.0% specificity, with positive and negative predictive values of 93.4% and 99.1%, respectively. The Tri-Combo test proved a reliable means to limit the use of individual parasite ELISAs to positive samples.

While death from diarrheal infections has decreased, levels of morbidity have not declined in comparison to historical levels and thus remain a significant health problem, especially in the developing world (7, 11). Three of the most common causes of protozoan-associated diarrheal infections are *Giardia* spp., *Cryptosporidium* spp., and *Entamoeba histolytica* (16). All three of these parasites are transmitted via a classical fecal-oral cycle (1). *Cryptosporidium* spp. are common throughout both the developed and developing world and can cause persistent diarrhea in HIV-infected individuals (2, 12, 19). Control of this organism can prove difficult due to its resistance to standard disinfection methods (e.g., chlorination of water sources) (3). *E. histolytica* is a single-cell ameba that is the cause of amebiasis (20). Clinical manifestations include diarrhea, dysentery, toxic megacolon, and liver abscess (5). The incidence of disease due to *Cryptosporidium* spp. and *E. histolytica*, and possibly *Giardia*, is increased with malnutrition (13, 14). Repeated infections can occur and can cause developmental delay in children (6, 15). Because treatment regimens for these infections are available, there is a need for rapid and cost-effective diagnostic screening methods (8, 10, 16, 17).

The Tri-Combo parasite screen test (TechLab, Blacksburg, VA), intended for clearance by the U.S. Food and Drug Administration (FDA), is an enzyme-linked immunosorbent assay developed to simultaneously detect *Giardia* spp., *Cryptosporidium* spp., and *E. histolytica* antigens in human fecal specimens. The microtiter plate format allows the rapid screening of large numbers of clinical specimens. Similar to other immunoassay-type tests for these three parasites, the Tri-Combo test is not designed for use with fixed fecal specimens. When a clinical sample is positive by the Tri-Combo test, additional testing for the presence of *Giardia* spp., *Cryptosporidium* spp., and/or *E. histolytica* parasites is indicated, as the test does not distinguish between these parasites.

A panel of 618 diarrheal and nondiarrheal human fecal specimens from male and female subjects aged 4 months to 89 years were tested with the Tri-Combo test at three international sites: 87 clinical samples at the National Institute for Infectious Disease (NIID) in Tokyo, Japan; 297 clinical samples at the International Center for Diarrheal Disease Research, Bangladesh (ICDDR,B), in Dhaka, Bangladesh; and 234 clinical samples at the Bernard Nocht Institute for Tropical Medicine (BNI) in Hamburg, Germany. All samples were tested with the FDA-approved individual Giardia II, *Cryptosporidium* II, and *E. Histolytica* II ELISAs (TechLab, Blacksburg, VA) as reference standards for the detection of each parasite. Samples for which the results differed between the Tri-Combo and the reference tests were reanalyzed with all tests, and if the final results still differed, the sample was recorded as a discrepant sample. Clinical samples that were positive in both the Tri-Combo and the corresponding reference standard test were scored as positive for parasite antigen. Samples discrepantly positive and negative on the Tri-Combo test versus the reference tests were considered false positives and false negatives, respectively.

The Tri-Combo parasite screen was performed following the manufacturer’s directions. All incubations were performed on the benchtop, and the results were analyzed on an ELISA-format spectrophotometer with the spectrophotometer absorbance set to read at 450 nm. The individual Giardia II, *Cryptosporidium* II, and *E. Histolytica* II tests were performed according to established protocols.

For the combined panel of samples tested at all three sites, the Tri-Combo test had a sensitivity of 97.9%, specificity of 97.0%, positive predictive value of 93.4%, and negative predictive value of 99.1% (Table 1). One hundred ninety-six samples were positive in the Tri-Combo test. According to the reference tests, the distribution of positive samples by organism was similar at the various sites; most samples were positive for *Giardia* spp. At the Tokyo site, 9 of 8 samples were *Giardia* positive, 4 were *Cryptosporidium* positive, and 3 were *E. histolytica* positive. At the Dhaka site, 68 sam-
ple was positive, 31 samples were Cryptosporidium positive, and 34 samples were E. histolytica positive. Finally, 35 samples were Giardia positive, 13 samples were Cryptosporidium positive, and 8 samples were E. histolytica positive at the Hamburg, Germany site. Of the four samples found to be false negatives in the Tri-Combo test, three were positive in the E. Histolytica II test and one in the Cryptosporidium II test. These results are similar to the performance of other available fecal-antigen-based assays for these protozoa. The reason for the discrepant results was unknown; the antigen detection levels between the Tri-Combo test and the reference tests do not differ significantly, and the few discrepant results we observed displayed a relatively even distribution between false positives and false negatives.

The Tri-Combo parasite screen test fills a niche in the diagnostic testing of diarrheal illness caused by protozoan infections, as there is currently no other test capable of specifically detecting in a single well Giardia spp., Cryptosporidium spp., and E. histolytica antigens in human clinical stool samples. There is one other rapid multiplex diagnostic test for these three parasites (the Triage parasite panel; Biosite, San Diego, CA), but unlike the Tri-Combo assay, it lacks specificity for E. histolytica, not being able to distinguish between this pathogen and the closely related human commensal Entamoeba dispar (4). A potential advantage of the Tri-Combo test over multiplex PCR-based tests for these parasites is that extensive training, equipment, and reagents needed for PCR are not required (9, 18). The Tri-Combo test demonstrated excellent positive predictive and negative predictive values when tested with a pool of clinical samples from three international sites. The format of the Tri-Combo test could be well suited to the testing of large numbers of clinical samples, as minimal laboratory expertise and reagents are necessary to run many samples simultaneously. Only samples that are positive would require further testing, and the subsequent tests could be similar ELISAs that are specific for the individual parasites (such as those used as the reference tests in this study). In conclusion, the Tri-Combo parasite screen test was demonstrated to be a useful tool in the detection of Giardia spp., Cryptosporidium spp., and E. histolytica antigens in human clinical stool samples.

ACKNOWLEDGMENTS

This work was supported by NIH grant AI43596 to W.A.P. and NIH R42 AI77171 to J.F.H. We thank TechLab, Inc., for the contribution of the Tri-Combo, Giardia II, Cryptosporidium II, and E. Histolytica II stool antigen detection tests. W.A.P. receives royalties from a licensing agreement for amebiasis diagnostics with TechLab, Inc. Those royalties are donated in their entirety to the American Society for Tropical Medicine and Hygiene without benefit to W.A.P.

REFERENCES